出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2021年11月
ASEANおよび北アジアのポイントオブケア/迅速診断市場: 製品（血糖モニタリング、COVID、HIV、STD、HAI、インフルエンザ、熱帯病および呼吸器疾患）、技術（迅速検査、分子診断）、ユーザー（病院、在宅医療） – 2026年までの予測
ASEAN and North Asian Point of Care/Rapid Diagnostics Market by Product (Glucose Monitoring, COVID, HIV, STDs, HAIs, Influenza, Tropical & Respiratory diseases), Technique (Rapid test, Molecular diagnostics), User (Hospital, Home Care) – Forecast to 2026
| ページ数 | 224 |
| 図表数 | 50 |
| 種別 | 英文調査報告書 |
–
| 目次 | お問合せ |
–
The ASEAN and North Asian Point of Care/Rapid Diagnostics market size is expected to grow from an estimated USD 2.0 billion in 2021 to USD 3.9 billion by 2026, at a CAGR of 13.0%. The growing demand for accurate and early diagnostic methodologies, modernization and expansion of healthcare infrastructure and significant disease prevalence are the major factors that are expected to drive the growth of the ASEAN and North Asian Point of Care/Rapid Diagnostics market during the forecast period.
“Infectious Disease Diagnostics are the largest product segment in the ASEAN and North Asian Point of Care/Rapid Diagnostics market”
Based on product, the ASEAN and North Asian Point of Care/Rapid Diagnostics market is segmented into Infectious Disease Diagnostics, Glucose Monitoring, Cancer Marker Testing, Cardiometabolic Monitoring, Cholesterol Testing, Coagulation Monitoring, Hematology Testing, Urinalysis, Drugs-of-abuse Testing, Pregnancy & Fertility Testing, Fecal Occult Testing and other PoC Diagnostic products. Infectious diseases are expected to account for the largest share of the ASEAN and North Asian Point of Care/Rapid Diagnostics market in 2021. Infectious disease diagnostics dominate the ASEAN and North Asian Point of Care/Rapid Diagnostics market owing to greater patient population and extensive market availability.
“Molecular Diagnostics is estimated to be having the highest demand in the technology segment in the ASEAN and North Asian Point of Care/Rapid Diagnostics market”
On the basis of technology, the ASEAN and North Asian Point of Care/Rapid Diagnostics market is segmented into Lateral Flow Assays, Immunoassays, Molecular Diagnostics, Microfluidics, Rapid Testing and Dipsticks. Molecular diagnostic technologies are projected to experience higher demand owing to supportive regulations, techno-commercial advantages, and rising public awareness.
“South Korea, Hong Kong, and Taiwan are among the top ASEAN countries to dominate the point of care diagnostics market.”
The ASEAN and North Asian Point of Care/Rapid Diagnostics market is segmented into South Korea, Hong Kong, Indonesia, Thailand, Philippines, Vietnam, Malaysia, Singapore, Taiwan, Myanmar, Laos and Cambodia. During the forecast period of 2021 to 2026, South Korea, Hong Kong and Taiwan will dominate the point of care diagnostics market. The high growth in this regional market is majorly attributed to factors such as the growing demand for accurate and early diagnostic methodologies.
Breakdown of Primaries:
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
•By Company Type: Tier 1–55%; Tier 2–20%; and Tier 3–25%
•By Designation: C Level–40%; Directors–35%; and Others–25%
•By Country: South Korea–14%; Singapore–11%; Malaysia–11%; Indonesia–10%; Taiwan–10%; and Others–44%
The major players operating in the ASEAN and North Asian Point of Care/Rapid Diagnostics market are Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Abbott Laboratories (US), Danaher Corporation (US), Becton, Dickinson and Company (US), Sysmex (Japan), Cardinal Health (US), Quidel (US), GE Healthcare (US) EKF Diagnostics (UK), bioMérieux SA (France), Accubiotech (China), PTS Diagnostics (US), Chembio Diagnostics (US) Trinity Biotech (Ireland), Johnson and Johnson(US), Sekisui Diagnostics (US), Nova Biomedical (US), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US) and Bio-Techne (US).
Product launches & approvals, mainly owing to the COVID-19 pandemic were the key strategies adopted by market players to achieve growth in the market.
Research Coverage:
This report studies the ASEAN and North Asian Point of Care/Rapid Diagnostics market based on product, technology, end user and country. The major market drivers and restraints are also covered in this report. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends, prospects, and contributions to the total market, and forecasts the revenue of the market segments with respect to four main regions.
Why Buy this Report?
1.The report identifies and addresses the key markets for the ASEAN and North Asian Point of Care/Rapid Diagnostics market, which would help equipment manufacturers and service providers review the growth in demand.
2.The report helps system providers understand the pulse of the market and provides insights into drivers, restraints, opportunities, and challenges.
3.The report will help key players understand the strategies of their competitors better and help them in making better strategic decisions.
目次
1INTRODUCTION
1.1OBJECTIVES OF THE STUDY
1.2MARKET DEFINITION
1.2.1MARKET SCOPE
1.2.2GEOGRAPHIC SCOPE
1.2.3YEARS CONSIDERED FOR THE STUDY
1.3CURRENCY USED FOR THE STUDY
1.4KEY STAKEHOLDERS
2RESEARCH METHODOLOGY
2.1RESEARCH DATA
2.1.1SECONDARY DATA
2.1.2PRIMARY DATA
2.2MARKET SIZE ESTIMATION METHODOLOGY
2.3MARKET DATA VALIDATION AND TRIANGULATION
2.4RESEARCH ASSUMPTIONS
2.5RESEARCH LIMITATIONS
3EXECUTIVE SUMMARY
FIGURE1: ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
FIGURE2: ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER
4MARKET OVERVIEW
4.1ASIA: MARKET DYNAMICS
4.1.1MAJOR DRIVERS
4.1.2KEY RESTRAINTS
4.1.3KEY GROWTH OPPORTUNITIES
4.1.4INDUSTRY-SPECIFIC CHALLENGES
4.2ASIA: PRICING TREND ANALYSIS FOR TARGET PRODUCT SEGMENTS (IN TERMS OF USD, AS OF 2020/21)
4.2.1ASEAN
4.2.2SOUTH KOREA
4.2.3GREATER CHINA
4.2.4OTHER ASIAN COUNTRIES
4.3ASIA: COVID-SPECIFIC INDUSTRY TRENDS
4.4ASIA: REGULATORY LANDSCAPE (AS OF 2020/21)
5POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY PRODUCT TYPE(USD MILLION; 2019 — 2026)*
TABLE 1ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 2ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
5.1INFECTIOUS DISEASE DIAGNOSTICS
5.1.1COVID TESTING
5.1.2HIV TESTING
5.1.3RESPIRATORY INFECTION TESTING
5.1.4INFLUENZA TESTING
5.1.5TROPICAL DISEASE TESTING
5.1.6STD TESTING
5.1.7HEPATITIS C TESTING
5.1.8HOSPITAL ACQUIRED INFECTION TESTING
5.1.9OTHER INFECTIOUS DISEASE TESTING
5.2GLUCOSE MONITORING
5.2.1GLUCOSE TEST STRIPS
5.2.2GLUCOMETERS
5.2.3LANCETS
5.3CARDIOMETABOLIC MONITORING
5.3.1CARDIAC MARKER TESTING
5.3.2HBA1C TESTING
5.3.3BLOOD GAS AND ELECTROLYTE TESTING
5.4COAGULATION MONITORING
5.5PREGNANCY AND FERTILITY TESTING
5.6URINALYSIS
5.7CANCER MARKER TESTING
5.8CHOLESTEROL TESTING
5.9HEMATOLOGY TESTING
5.10FECAL OCCULT TESTING
5.11DRUG OF ABUSE TESTING
5.12OTHER POC PRODUCTS
6POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY TECHNOLOGY(USD MILLION; 2019 — 2026)*
TABLE 3ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
6.1RAPID TESTS
6.2IMMUNOASSAY
6.3LATERAL FLOW ASSAY
6.4MICROFLUIDICS
6.5MOLECULAR DIAGNOSTICS
6.6DIPSTICKS
7POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY END USER (USD MILLION; 2019 — 2026)*
TABLE 4ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
7.1HOSPITALS AND CRITICAL CARE CENTERS
7.2OUTPATIENT AND AMBULATORY CARE CENTERS
7.3HOME CARE
7.4OTHER END USERS
8POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY COUNTRY (USD MILLION; 2019 — 2026)*
8.1INDONESIA
TABLE 5INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 6INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 7INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 8INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.2LAOS AND CAMBODIA
TABLE 9LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 10LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 11LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 12 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.3MALAYSIA
TABLE 13MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 14MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 15MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 16 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.4MYANMAR
TABLE 17 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 18MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 19MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 20 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.5PHILIPPINES
TABLE 21 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 22PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 23PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 24 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.6SINGAPORE
TABLE 25 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 26SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 27SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 28 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.7THAILAND
TABLE 29 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 30THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 31THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 32 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.8VIETNAM
TABLE 33 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 34VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 35VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 36 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.9SOUTH KOREA
TABLE 37 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 38SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 39SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 40 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.10HONG KONG
TABLE 41 HONG KONG KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 42HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 43HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 44 HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.11TAIWAN
TABLE 45 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USDMILLION)
TABLE 46TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 47TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 48 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1OVERVIEW
9.2ASEAN: POINT OF CARE DIAGNOSTICS MARKET SHARE ANALYSIS BY TOP 5 VENDORS (IN TERMS OF %REVENUE, IN 2020)
9.3ASEAN: COMPETITIVE SCENARIO (2018-2021)
9.3.1PRODUCT LAUNCHES
9.3.2AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
9.3.3GEOGRAPHIC EXPANSIONS
9.3.4ACQUISTIONS
9.4ASEAN: COMPETITIVE LEADERSHIP MAPPING FOR MAJOR PLAYERS (AS OF 2021)
9.4.1PARTICIPANTS
9.4.2EMERGING LEADERS
9.4.3PERVASIVE PLAYERS
9.4.4STARS
10COMPANY PROFILES**
(Business overview, product portfolio, industry-specific developments in 2018-2021***)
10.1ABBOTT LABORATORIES
10.2ACCUBIOTECH
10.3BECTON. DICKINSON AND COMPANY
10.4JOHNSON & JOHNSON
10.5BIOMERIEUX
10.6GE HEALTHCARE
10.7ORTHOCLINICAL DIAGNOSTICS
10.8BIOTECHNE
10.9EKF DIAGNOSTICS
10.10SYSMEX
10.11ROCHE DIAGNOSTICS
10.12SEKISUI DIAGNOSTICS
10.13SIEMENS HEALTHINEERS
10.14THERMO FISHER SCIENTIFIC
10.15TRINITY BIOTECH
10.16 CHEMBIO
10. 17CARDINAL HEALTH
10. 18 PTS DIAGNOSTICS
10.19QUIDEL
10.20 INSTRUMENTATION LABORATORY (A WERFEN COMPAN
11APPENDIX
お問合せフォーム
